Philip Hemme, Author at Labiotech.eu

About

Young French-German Entrepreneur, Co-founder & CEO of Labiotech.eu. High-level table tennis player, and German beer/French Wine lover 🙂

Articles by Philip Hemme

News and Trends 23 Jul 2015

MorphoSys’ blood disorder antibody reaches Phase I

MorphoSys AG seems to be sitting on a goldmine with its Human Combinatorial Antibody Library (HuCAL). The German giant snatched the second milestone payment from Novartis this year. The latter will now initiate a Phase I test for a HuCAL antibody designed to treat blood disorders. MorphoSys landed some big accounts in the past. Pfizer, Bayer, […]

July 23, 2015 - 2 minutesmins - By Philip Hemme

sugar beet global bioenergies first generation biofuel

News and Trends 23 Jul 2015

Why is Global Bioenergies moving back to First-Generation Biofuels?

Second-generation biofuels have solved many problems caused by their predecessors, first-generation biofuels. The French synthetic biology company Global Bioenergies just announced that it has adapted its gaz-producing process to sucrose, a first-generation biofuel. Why would it make this step backwards? Global Bioenergies is one of the leading European industrial Biotech companies. It wants to replace fossil oil with a biosourced […]

July 23, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 23 Jul 2015

Man can See Again thanks to his Bionic Eye

Major Breakthrough in eye research! The world’s first ever dry Age Related Macular Degeneration patient received Second Sight Medical Products’ ‘bionic eye’. Initial tests on the 80-year-old individual with no central vision showed that the treatment allowed him to see the outline of people again. 80-year-old Ray Flynn, from Audenshaw in Manchester, is one of the 20 […]

July 23, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 22 Jul 2015

Sensorion raises an additional €8M to test its inner ear drug

Listen up! French biotech Sensorion just raised €8M through a private placement to advance its inner ear disease drug to Phase II. Since its IPO in April, the value of the company has quadrupled. Sensorion emerged in 2009 as a spin-off of Inserm, the French institute of health and medical research. It specialises in the treatment of […]

July 22, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 22 Jul 2015

Nanopore cashes in €100M to revolutionize Next-gen sequencing

Personalized medicine is now becoming a reality thanks to next-gen sequencing. Illumina still remains Number 1 in the field, but Oxford Nanopore is on its way up to the top of the charts. The UK-based company raised €100M to become a serious challenger with its cheap and small technology. Oxford Nanopore Technologies, a spin out […]

July 22, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 21 Jul 2015

NASDAQ-listed Biotech from Boston shops cancer-treating antibodies in Italy

A new partnering deal in the trendy field of immune-oncology. Boston-based Agenus signed a €40M deal with Italian Biotech Diatheva to get antibodies, which are targeting a glycoprotein expressed on T cell and NK cell lymphocytes to boost the immune system of patients to fight major cancer. The Boston (Lexington)-based company Agenus went on the NASDAQ […]

July 21, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 21 Jul 2015

BMS steps into the European Market with its new Lung Cancer Treatment

It’s the first major treatment for metastatic squamous non-small cell lung cancer (NSCLC) to have been approved in over a decade in Europe: Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Nivolumab was granted with market authorization by the European Commission. The drug is the first to improve overall survival in previously-treated metastatic NSCLC. Just one month […]

July 21, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 21 Jul 2015

Genetically Modified Insects: Designed to Cause Extinction

Insects can be very dangerous creatures, spreading diseases and destroying the yield. The British biotech company Oxitec developed a unique approach to potentially wipe out some harmful populations of these tiny animals. Studies on the diamondback moth are already showing good results! Farmers around the world struggle with a serious pest caused by the diamondback moth […]

July 21, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 20 Jul 2015

InnaVirVax Raises €3.6M to Speed Up its HIV Vaccine

HIV is definitely under the spotlight today. Just after Theravectys’ announcement about its phase I/II success, InnaVirVax completed a third funding round to accelerate its Phase 2 clinical development. The first-in-class immunotherapy designed to treat HIV infections gained further support by all the historical investors in the company. Since 1987, HIV has mainly been treated with a combination of […]

July 20, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 20 Jul 2015

DBV raised €255M on the NASDAQ

[Update 20/07/2015] After successfully closing its Underwritten Public Offering, DBV finally raised €255M ($281,5M) on the NASDAQ. Original article from 16/07/2015: DBV Technologies is going for its second fundraising on the NASDAQ, hoping for €223M. €68.6M were already secured last week from Baker Bros. Advisors LP. The money will allow the company to stay independent all […]

July 20, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 17 Jul 2015

AC Immune receives Milestone Payment for Alzheimer Antibody

AC Immune received a first milestone payment from Roche’s subsidiary Genentech. The latter picked up a potential Alzheimer’s drug worth developing towards clinical trials. The collaboration began in 2012 with Genentech’s promising milestone payments amounting to more than €384M (CHF400M). Alzheimer’s disease will be one of the biggest burdens of tomorrow’s society showing a dramaticaly […]

July 17, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 15 Jul 2015

How Servier saved Cellectis, the French CAR-T Miracle

Cellectis, the €1bn CAR-T company, just announced it reached a significant milestone in its collaboration with Servier. Surprisingly, early 2014, Cellectis and its 300 employees were only three months away from bankruptcy, mainly because of the competing gene-editing technology CRISPR. How and why did Servier save them? Let’s find out. Cellectis was founded in 1999 in Paris and […]

July 15, 2015 - 5 minutesmins - By Philip Hemme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Philip Hemme

About

Articles by Philip Hemme

MorphoSys’ blood disorder antibody reaches Phase I

Why is Global Bioenergies moving back to First-Generation Biofuels?

Man can See Again thanks to his Bionic Eye

Sensorion raises an additional €8M to test its inner ear drug

Nanopore cashes in €100M to revolutionize Next-gen sequencing

NASDAQ-listed Biotech from Boston shops cancer-treating antibodies in Italy

BMS steps into the European Market with its new Lung Cancer Treatment

Genetically Modified Insects: Designed to Cause Extinction

InnaVirVax Raises €3.6M to Speed Up its HIV Vaccine

DBV raised €255M on the NASDAQ

AC Immune receives Milestone Payment for Alzheimer Antibody

How Servier saved Cellectis, the French CAR-T Miracle

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Philip Hemme

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!